Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Clin Lymphoma Myeloma Leuk ; 20(9): 624-631.e2, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32611506

RESUMEN

BACKGROUND: Erythrodermic cutaneous T-cell lymphoma consists of erythrodermic mycosis fungoides and Sézary syndrome. Previous studies have indicated that very large Sézary cells (> 14 µm diameter) or the presence of aneuploid cells in the blood might reflect large-cell transformation, with a corresponding poor prognosis. PATIENTS AND METHODS: A retrospective study assessed data between June 1997 and April 2002 of 32 patients with erythrodermic cutaneous T-cell lymphoma, 4 patients with leukemic mycosis fungoides, and 19 patients with nonneoplastic inflammatory conditions who were referred for evaluation of possible cutaneous T-cell lymphoma. Data were studied by 2-parameter flow cytometry gated on the lymphocyte population. RESULTS: High-scatter T lymphocytes (HSL) were detected in initial blood samples from 10 of 19 patients with Sézary syndrome, 1 of 13 patients with erythrodermic mycosis fungoides, and no patient with nonneoplastic inflammatory conditions. A significant correlation was found between HSL and very large Sézary cells and histopathologic evidence of large-cell transformation. Moreover, the presence of HSL suggests a poor prognosis even for patients with advanced disease. CONCLUSION: We propose that HSL are often large transformed neoplastic Sézary cells that may be detected in patients with clinically unapparent large-cell transformation.


Asunto(s)
Transformación Celular Neoplásica/metabolismo , Linfocitos/metabolismo , Linfoma Cutáneo de Células T/sangre , Síndrome de Sézary/sangre , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
2.
BMC Cancer ; 19(1): 913, 2019 Sep 13.
Artículo en Inglés | MEDLINE | ID: mdl-31514735

RESUMEN

BACKGROUND: Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal neoplasm of the gastrointestinal tract. Mutations of KIT and platelet-derived growth factor receptor alpha have been well characterized in GISTs. Patients with KIT mutations are generally sensitive to treatment with tyrosine kinase inhibitors. However, some patients with GIST, while initially sensitive to TKIs, gain resistance in later stages of treatment. Heterologous rhabdomyomsarcomatous dedifferentiation of advanced GISTs after long-term imatinib mesylate (IM) therapy has been reported. In these cases, the underlying molecular mechanism of tumor progression and transformation is unclear. CASE PRESENTATION: We report one such patient with rhabdomyosarcomatous dedifferentiation of a GIST without metastatic disease after brief 3-month therapy with IM. The tumor was composed of two distinct phenotypes, a CD117 negative region with rhabdomyosarcomatous differentiation directly adjacent to a CD117 positive classic GIST region. Molecular analysis identified the activating KIT exon 11 mutation in both regions, indicating a common origin for both phenotypes. Additionally, the dedifferentiated component contained two synonymous variants in platelet-derived growth factor receptor alpha and KIT. The increased number of synonymous variants in the rhabdomyosarcomatous region may reflect increased genetic instability of this tumor that may have resulted in the loss of CD117 expression in the dedifferentiated component. CONCLUSION: This study adds to the growing consensus that rhabdomyosarcomatous GIST progresses from a common GIST primary tumor. The role of IM in this progression is uncertain; however short duration of IM treatment in this study supports the hypothesis that rhabdomyosarcomatous GIST progression is not a consequence of IM therapy. Furthermore, we provide additional information supporting the observation that CD117 negative rhabdomyosarcomatous transformation maintains the activating KIT variant without KIT expression.


Asunto(s)
Transformación Celular Neoplásica , Tumores del Estroma Gastrointestinal/diagnóstico , Rabdomiosarcoma/patología , Anciano , Transformación Celular Neoplásica/genética , Análisis Citogenético , Tumores del Estroma Gastrointestinal/genética , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Inmunohistoquímica , Masculino , Mutación , Proteínas Proto-Oncogénicas c-kit/genética , Rabdomiosarcoma/diagnóstico por imagen , Rabdomiosarcoma/genética , Tomografía Computarizada por Rayos X
3.
J Biomed Mater Res B Appl Biomater ; 107(7): 2409-2418, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-30784181

RESUMEN

Stress urinary incontinence (SUI), a serious condition which affects ~56% of postmenopausal women, is the involuntary leakage of urine through urethra during physical activity that causes an increase in abdominal pressure. SUI is associated with a decrease in compliance and volume of urethral tissue, likely due to a reduced proteoglycan: collagen ratio in the extracellular matrix and collagen disorganization. Here, we investigated the use of biomimetic proteoglycans (BPGs) to molecularly engineer urethral tissue of New Zealand White rabbits to examine biocompatibility in vivo. BPG concentrations of 50 mg/mL (n = 6, 1 week) and 200 mg/mL (n = 6, 1 week and n = 6, 6 weeks) dissolved in 1× phosphate-buffered saline (PBS) were injected transurethrally using a 9 French cystoscope, and were compared to PBS-injected controls (n = 3, 1 week) and non-injected controls (n = 2, 1 week). Urethral compression pressure measurements confirm BPG injections did not modify normal urethral pressure, as intended. Histological assessment demonstrated biological tolerance of BPGs in urethra and no inflammatory response was detected after 1 and 6 weeks compared to non-injected controls. Confocal imaging of fluorescently-labeled BPG injected urethral specimens demonstrated the integration of BPGs into the interstitial connective tissue and confirmed they were still present after 6 weeks. A general decrease of collagen density was exhibited near injection sites which may be due to increased hydration induced by BPGs. Injection of BPGs is a novel approach that demonstrates potential as molecular treatment for SUI and may be able to reverse some of the degenerative tissue changes of individuals affected by this condition. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: 00B: 000-000, 2019. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 2409-2418, 2019.


Asunto(s)
Materiales Biomiméticos/química , Matriz Extracelular/química , Proteoglicanos/química , Ingeniería de Tejidos , Uretra , Incontinencia Urinaria de Esfuerzo , Animales , Conejos , Uretra/metabolismo , Uretra/patología , Incontinencia Urinaria de Esfuerzo/metabolismo , Incontinencia Urinaria de Esfuerzo/patología , Incontinencia Urinaria de Esfuerzo/terapia
4.
J Orthop Res ; 37(2): 403-411, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30480335

RESUMEN

Biomimetic proteoglycans (BPGs) have the potential to treat osteoarthritis (OA) given that these molecules mimic the structure and properties of natural proteoglycans, which are significantly reduced in OA. We examined the effects of BPGs injected into the intra-articular space in an in vivo OA rabbit knee model and evaluated the effect on histological response, joint friction, and BPG distribution and retention. Rabbits underwent ACL transection to create an arthritic state after 5 weeks. OA rabbits were treated with BPGs or Euflexxa® (hyaluronic acid) intra-articular injections. Non-OA rabbits were injected similarly with BPGs; contralateral joints served as controls. The progression of OA and response to injections were evaluated using Mankin and gross grading systems indicating that mild OA was achieved in operated joints. The coefficient of friction (COF) of the intact knee joints were measured using a custom pendulum friction apparatus, showing that OA joints and OA + Euflexxa® joints demonstrated increased COF than non-operated controls, while BPG-injected non-OA and OA + BPGs were not significantly different from non-OA controls. Injected fluorescently labeled BPGs demonstrated that BPGs diffused into cartilage with localization in the pericellular region. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:403-411, 2019.


Asunto(s)
Osteoartritis de la Rodilla/tratamiento farmacológico , Proteoglicanos/uso terapéutico , Animales , Materiales Biomiméticos , Cartílago Articular/patología , Evaluación Preclínica de Medicamentos , Femenino , Colorantes Fluorescentes , Fricción/efectos de los fármacos , Osteoartritis de la Rodilla/patología , Proteoglicanos/farmacología , Conejos
5.
Pediatr Neurosurg ; 53(5): 311-316, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30110687

RESUMEN

Primary central nervous system lymphoma (PCNSL) is rare in children with immunocompromise as an important risk factor. A 7-year-old girl with unspecified T-cell immunodeficiency presented with left-sided weakness and was found to have a right-sided frontal lobe mass on imaging. The mass was resected; histopathology and molecular studies evidenced diffuse large B-cell lymphoma. Prior chest imaging had revealed left upper lobe mass, and repeat chest imaging revealed multiple pulmonary nodules, initially concerning for metastasis. Video-assisted thoracoscopic surgical wedge resection of the lung mass was performed; the molecular profile was distinct from the PCNSL, suggesting synchronous de novo lymphomagenesis of brain and pulmonary primaries.


Asunto(s)
Neoplasias del Sistema Nervioso Central/patología , Neoplasias del Sistema Nervioso Central/cirugía , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Linfoma de Células B Grandes Difuso/patología , Neoplasias Primarias Múltiples/patología , Neoplasias Primarias Múltiples/cirugía , Neoplasias del Sistema Nervioso Central/diagnóstico por imagen , Niño , Diagnóstico Diferencial , Femenino , Lóbulo Frontal , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Linfoma de Células B Grandes Difuso/diagnóstico por imagen , Linfoma de Células B Grandes Difuso/cirugía , Imagen por Resonancia Magnética , Neoplasias Primarias Múltiples/diagnóstico por imagen , Cirugía Torácica Asistida por Video/métodos
6.
Leuk Lymphoma ; 59(2): 330-339, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-28595473

RESUMEN

Bernengo et al. reported that >30% CD4+CD26- lymphocytes detect blood involvement in patients with mycosis fungoides (MF) and Sézary syndrome. In addition, the ISCL/EORTC suggested that this threshold might serve as a criterion for the B2 blood rating for staging. In this manuscript, we report our experience with measurement of CD4+CD26- and CD4+CD7- cells, Sézary cell counts, and aberrant T cells with diminished expression of CD2, CD3, or CD5 antigens. CD4+CD26- ≥30% occurred in 15 of 373 (4.0%) patients with MF, 33 of 47 (70%) patients with erythrodermic cutaneous T cell lymphoma (ECTCL) and 2 of 54 (4%) patients with inflammatory skin diseases. CD4+CD26- measurements provided a more reliable assessment of neoplastic cell numbers in the blood than Sézary cell or CD4+CD7- percentages. CD4+CD26- measurements may be used to define B ratings for staging with B2 defined as CD4+CD26- ≥ 1000/µL, plus clonality or phenotypically abnormal cells.


Asunto(s)
Biomarcadores de Tumor , Linfocitos T CD4-Positivos/patología , Linfoma Cutáneo de Células T/diagnóstico , Subgrupos de Linfocitos T/patología , Linfocitos T CD4-Positivos/metabolismo , Diagnóstico Diferencial , Dipeptidil Peptidasa 4/metabolismo , Femenino , Humanos , Recuento de Linfocitos , Linfoma Cutáneo de Células T/sangre , Masculino , Micosis Fungoide/sangre , Micosis Fungoide/diagnóstico , Metástasis de la Neoplasia , Estadificación de Neoplasias , Pronóstico , Síndrome de Sézary/sangre , Síndrome de Sézary/diagnóstico , Subgrupos de Linfocitos T/metabolismo
7.
Case Rep Hematol ; 2016: 6054017, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27752371

RESUMEN

Myeloproliferative neoplasms (MPNs) are hematopoietic malignancies characterized by unchecked proliferation of differentiated myeloid cells. The most common BCR-ABL1-negative MPNs are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The discovery of JAK2 V617F mutation has improved our understanding of the molecular basis of MPN. The high frequency of JAK2 mutation in MPN makes JAK2 mutation testing an essential diagnostic tool and potential therapeutic target for MPN. Here, we present a rare case of a 34-year-old patient who was initially diagnosed with acute myeloid leukemia (AML) with mutated NPM1. After chemotherapy treatment followed by granulocyte colony stimulating factor administration, the patient achieved complete remission of AML. However, the bone marrow showed hypercellularity with granulocytic hyperplasia, markedly increased atypical megakaryocytes (50.2/HPF) with focal clustering, and reticulin fibrosis (3/4). JAK2 V617F mutation was also detected. Considering the possibility of AML transformed from a previous undiagnosed MPN, patient underwent peripheral blood allogenic stem cell transplant. This case illustrates the diagnostic challenges of firmly establishing a diagnosis between similar, but distinct, disease entities and an accurate clinicopathological differentiation is crucial.

8.
Anal Quant Cytopathol Histpathol ; 35(6): 301-5, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24617035

RESUMEN

OBJECTIVE: To explore thymidine phosphorylase (TP) expression in B-cell lymphomas (BCLs). TP is expressed by tumor and stromal cells in a variety of cancers. STUDY DESIGN: Paraffin-embedded tissues from follicular lymphomas, diffuse large BCLs (DLBCLs), and benign lymph nodes were studied using immunohistochemical staining with antibodies for TP and CD68. Prognostic markers were used to stain DLBCLs. We correlated TP expression in DLBCL indirectly with prognostic immunomarkers and directly with survival data. RESULTS: TP expression in BCLs was noted in a subset of malignant B cells. TP expression in higher-grade lymphoma was identified in 66% of cases and 11% of lower-grade lymphomas. Macrophages/stromal cells demonstrated an intense cytoplasmic and/or nuclear staining pattern in both lymphoma and benign lymph nodes, confirmed by CD68 coexpression. Increased macrophage/ stromal cells in higher-grade lymphomas are associated with enhanced TP expression in neoplastic B cells (observation only). Sixty-eight percent of TP-positive DLBCLs were of nongerminal center origin, indicating poorer prognosis. CONCLUSION: TP is more likely expressed by malignant B cells in higher-grade lymphomas, and expression of TP possibly results from changes intrinsic to the tumor cells or interactions between microenvironment and tumor. TP positivity in DLBCL correlates with nongerminal center origin and worse outcome.


Asunto(s)
Biomarcadores de Tumor/análisis , Linfoma de Células B/enzimología , Linfoma de Células B/patología , Timidina Fosforilasa/biosíntesis , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Linfoma de Células B/mortalidad , Pronóstico , Estudios Retrospectivos , Timidina Fosforilasa/análisis
9.
J Mol Diagn ; 14(5): 510-7, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22749746

RESUMEN

For patients with primary lung cancer, accurate determination of the tumor type significantly influences treatment decisions. However, techniques and methods for lung cancer typing lack standardization. In particular, owing to limited tumor sample amounts and the poor quality of some samples, the classification of primary lung cancers using small preoperative biopsy specimens presents a diagnostic challenge using current tools. We previously described a microRNA-based assay (miRview squamous; Rosetta Genomics Ltd., Rehovot, Israel) that accurately differentiates between squamous and nonsquamous non-small cell lung cancer. Herein, we describe the development and validation of an assay that differentiates between the four main types of lung cancer: squamous cell carcinoma, nonsquamous non-small cell lung cancer, carcinoid, and small cell carcinoma. The assay, miRview lung (Rosetta Genomics Ltd.), is based on the expression levels of eight microRNAs, measured using a sensitive quantitative RT-PCR platform. It was validated on an independent set of 451 samples, more than half of which were preoperative cytologic samples (fine-needle aspiration and bronchial brushing and washing). The assay returned a result for more than 90% of the samples with overall accuracy of 94% (95% CI, 91% to 96%), with similar performance observed in pathologic and cytologic samples. Thus, miRview lung is a simple and reliable diagnostic assay that offers an accurate and standardized classification tool for primary lung cancer using pathologic and cytologic samples.


Asunto(s)
Neoplasias Pulmonares/clasificación , Neoplasias Pulmonares/diagnóstico , MicroARNs/genética , Técnicas de Diagnóstico Molecular/métodos , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Pulmonares/genética , Análisis de Secuencia por Matrices de Oligonucleótidos/métodos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
10.
Adv Hematol ; 2011: 875135, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22162690

RESUMEN

Thymidine phosphorylase may be overexpressed in both neoplastic cells and tumor stromal cells in a variety of malignancies. Our study explores thymidine phosphorylase expression in lymph nodes (LNs) from patients with mycosis fungoides (MF) or Sézary syndrome (SS). In MF/SS, the LNs may have a pathologic diagnosis of either dermatopathic lymphadenopathy (LN-DL) or involvement by MF/SS (LN-MF). We performed immunohistochemical staining on MF/SS lymph nodes using antibodies to thymidine phosphorylase, CD68, CD21, CD3, and CD4. In both LN-DL and benign nodes, thymidine phosphorylase staining was noted only in macrophages, dendritic cells, and endothelial cells. In LN-MF, thymidine phosphorylase expression was also noted in subsets of intermediate to large neoplastic T cells. Concurrent CD68, CD21, CD3, and CD4 staining supported the above observations. Similar results were noted in the skin and in LN-MF with large cell transformation. Other T-cell lymphomas were also examined (total 7 cases); only enteropathy-type T-cell lymphoma (1 case) showed TP positivity in neoplastic T lymphocytes. We demonstrated that thymidine phosphorylase staining is present in neoplastic T cells in mycosis fungoides. The exact mechanism needs further investigation.

11.
Clin Lymphoma Myeloma Leuk ; 11(6): 453-61, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21940235

RESUMEN

Cutaneous and systemic plasmacytosis (C/SP), human herpes virus-8 (HHV8), negative multicentric plasmacytic Castleman disease (MPCD), and idiopathic plasmacytic lymphadenopathy are polyclonal plasma cell proliferations of unknown etiology that predominantly affect Asian individuals. Herein, we present our experience with a Vietnamese man with typical C/SP limited to the skin but, after 10 years, may have developed perirenal involvement, and with a white man with human immunodeficiency virus and HHV8 negative MPCD with involvement of skin, lymph nodes, and kidneys at presentation, and who later succumbed to gastric carcinoma. Based on a review of the literature, we suggest that C/SP, cutaneous MPCD, and idiopathic plasmacytic lymphadenopathy with skin involvement are part of a continuum rather than distinct entities and, as such, may be regarded as variants of HHV8-negative MPCD. Although the majority of patients with C/SP run a chronic benign course, special attention should be given to monitoring for pulmonary and renal involvement. We hypothesize that long-lived plasma cells originate and survive in the environment of the skin akin to other stromal "survival" niches due to the local production of interleukin 6 and that such patients might respond to agents that interfere with interleukin-6 activity.


Asunto(s)
Enfermedad de Castleman/patología , Hipergammaglobulinemia/patología , Células Plasmáticas/patología , Enfermedades de la Piel/patología , Humanos , Masculino , Persona de Mediana Edad
12.
Anal Quant Cytol Histol ; 32(3): 161-5, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20701070

RESUMEN

OBJECTIVE: To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions. STUDY DESIGN: A retrospective review of 89 consecutive body fluid specimens with concurrent FCM analysis during 2001 to 2006 was performed. The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM. RESULTS: The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%). In patients without any prior clinical history, FCM study was positive in 2 cases and negative in 49 cases. In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases. In patients with a prior clinical history, FCM was positive in 23 cases and negative in 15 cases. CONCLUSION: FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management. In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.


Asunto(s)
Líquido Ascítico/patología , Citometría de Flujo/métodos , Neoplasias Hematológicas/diagnóstico , Derrame Pericárdico/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Líquido Ascítico/inmunología , Líquido Ascítico/metabolismo , Biomarcadores de Tumor/inmunología , Biomarcadores de Tumor/metabolismo , Niño , Femenino , Neoplasias Hematológicas/inmunología , Neoplasias Hematológicas/metabolismo , Humanos , Inmunofenotipificación , Masculino , Persona de Mediana Edad , Derrame Pericárdico/inmunología , Derrame Pericárdico/metabolismo , Reproducibilidad de los Resultados , Estudios Retrospectivos , Adulto Joven
13.
Digit J Ophthalmol ; 16(3): 9-12, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-23362375

RESUMEN

We report a case of diffuse large B-cell lymphoma in a 46-year-old female presenting in an unusual manner with stage IVB disease including concurrent orbital and leptomeningeal involvement. The cytologic features and cytogenetics of the malignancy are noted, and the management and progression of the disease, with attention to orbital involvement, is recorded for a period of over 2.5 years, until the patient's death.

14.
Ann Diagn Pathol ; 12(3): 212-6, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18486899

RESUMEN

Combination of the splenic marginal zone B-cell lymphoma (SMZL) and classical Hodgkin lymphoma (cHL) is extremely rare. We report a unique case with concurrent SMZL and cHL. The patient was a 63-year-old man who presented with fatigue and anemia, showing a splenomegaly and retroperitoneal lymphadenopathy. A splenectomy revealed monotonous marginal zone lymphocytic infiltrates and numerous large Reed-Sternberg-like cells. Flow cytometry revealed a kappa light-chain-restricted CD5 (-), CD23 (-) B-cell population. DNA polymerase chain reaction analysis confirmed the presence of clonal rearrangement of the immunoglobulin heavy-chain gene. Immunohistochemical studies revealed that the large atypical cells were CD30 (+), CD15 (weakly +), CD20 (-), CD45 (-), Pax5 (weakly +), BOB.1 (-), and Oct2 (-), indicating the coexistence of SMZL with cHL. After the chemotherapy, the patient achieved a clinical/radiologic remission, whereas cHL was detected in liver and bone marrow subsequently. The case indicates that both components of lymphoma can present concurrently as a composite form of lymphoma and both need to be treated adequately.


Asunto(s)
Enfermedad de Hodgkin/patología , Linfoma de Células B de la Zona Marginal/patología , Neoplasias Primarias Secundarias/patología , Neoplasias del Bazo/patología , Antígenos CD/análisis , Linfocitos B/química , Linfocitos B/patología , Terapia Combinada , Reordenamiento Génico de Cadena Pesada de Linfocito B/genética , Enfermedad de Hodgkin/genética , Enfermedad de Hodgkin/terapia , Humanos , Enfermedades Linfáticas , Linfoma de Células B de la Zona Marginal/genética , Linfoma de Células B de la Zona Marginal/terapia , Masculino , Persona de Mediana Edad , Células de Reed-Sternberg/patología , Inducción de Remisión , Neoplasias del Bazo/genética , Neoplasias del Bazo/terapia , Esplenomegalia
15.
Dermatology ; 216(1): 68-75, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18032903

RESUMEN

INTRODUCTION: The simultaneous presentation of chronic B-cell lymphocytic leukemia (B-CLL) and cutaneous T-cell lymphoma (CTCL) is extremely rare. CASE REPORT: We describe a patient with B-CLL and Sézary syndrome (SS), an erythrodermic and leukemic variant of CTCL. Despite treatment, the SS progressed to involve internal organs and eventual death of the patient from sepsis. This is the first reported case of SS coexisting with chronic lymphocytic leukemia in which an anti-V beta 13.6 antibody was used to serially track changes in circulating neoplastic T cells vis-à-vis neoplastic B cells and to detect neoplastic T cells in ascitic fluid near the end of the patient's life. DISCUSSION: We speculate that the coexistence of B-CLL and CTCL is the result of an initiating genetic or epigenetic defect at the level of the common lymphoid stem cell that predisposes both B-cell and T-cell lineages to additional oncogenic changes at a more advanced stage of differentiation.


Asunto(s)
Leucemia Linfocítica Crónica de Células B/complicaciones , Síndrome de Sézary/complicaciones , Neoplasias Cutáneas/complicaciones , Anciano , Anciano de 80 o más Años , Antígenos CD/análisis , Linfocitos B/metabolismo , Resultado Fatal , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/inmunología , Leucemia Linfocítica Crónica de Células B/patología , Masculino , Persona de Mediana Edad , Receptores de Antígenos de Linfocitos T alfa-beta/análisis , Síndrome de Sézary/inmunología , Síndrome de Sézary/patología , Piel/patología , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/patología , Linfocitos T/metabolismo
16.
Anal Quant Cytol Histol ; 29(5): 333-8, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17987814

RESUMEN

OBJECTIVE: To demonstrate the unique morphologic and phenotypic features observed in cases of T-cell lymphomas presenting as effusions. STUDY DESIGN: Cytologic slides and flow cytometric histograms of 8 cases of body fluids with T-cell lymphoma were retrospectively reviewed. Morphologic features, flow cytometric histograms and immunophenotypes of the cells were evaluated. RESULTS: Three of the 8 cases showed 1 or more of the following: intermediate-to-large cells with an increased nuclear-cytoplasmic ratio, finely granular or vacuolated cytoplasm and round or convoluted vesicular nuclei with a prominent single or multiple nucleoli. Flow cytometric studies of these 3 cases showed an abnormal scatter pattern in the myelomonocytic region of the histograms. Phenotypic analysis revealed variable expression of a T-cell phenotype. The remaining cases showed the conventional morphologic and flow cytometric features of a T-cell lymphoma. CONCLUSION: Morphologic alterations of neoplastic T-cells in body fluids can result in a variety of potentially incorrect diagnoses. The unusual flow cytometric histogram can serve as a useful clue for the diagnosis of T-cell lymphoma in body fluids but could be a potential pitfall for a false negative. Detailed cytologic evaluation combined with flow cytometric study can improve diagnostic accuracy.


Asunto(s)
Citodiagnóstico , Linfoma de Células T/patología , Anciano , Líquidos Corporales/citología , Citometría de Flujo , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Fenotipo
17.
Ann Diagn Pathol ; 10(5): 257-62, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16979516

RESUMEN

Lipofuscin, known as the "wear and tear" pigment, is seen in cells undergoing regressive changes, the seminal vesicles and the ejaculatory ducts. It is also present in prostatic adenocarcinoma. The purpose of this study is to evaluate the prognostic significance of lipofuscin in prostatic adenocarcinoma. Lipofuscin was evaluated in 736 hematoxylin-eosin-stained slides from 60 conventional and whole-mounted consecutive radical prostatectomies from December 1996 to February 2002. The adenocarcinoma cases were divided into lipofuscin-positive group and lipofuscin-negative group. The Gleason score and pathologic stage were compared between the 2 groups. Percentage of cells positive for p53 and MIB-1 was also compared. Lipofuscin pigment was found in 17 (31%) of 60 prostatic adenocarcinomas as random, sparse, fine, yellow-brown intracytoplasmic granules staining positive for cathepsin D and negative for S-100 protein. Using logistic regression to exclude age as a confounding factor, lower Gleason scores and pathologic stages were demonstrated in the lipofuscin-positive group. There was also a significant difference between the 2 groups in tumor volume, degree of capsular invasion, and positive margins. The difference in seminal vesicle invasion and vascular invasion between the 2 groups was not statistically significant. Lipofuscin in prostatic adenocarcinoma correlates with both lower Gleason score and pathologic stage. Lipofuscin probably indicates slow cellular turnover as suggested by the low proliferation rate and p53 expression. The value of lipofuscin in biopsy as a predictor separating aggressive from indolent disease needs further investigation.


Asunto(s)
Adenocarcinoma/metabolismo , Biomarcadores de Tumor/metabolismo , Lipofuscina/metabolismo , Neoplasias de la Próstata/metabolismo , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Anciano , Biopsia , Proliferación Celular , Regulación Neoplásica de la Expresión Génica , Humanos , Antígeno Ki-67/genética , Antígeno Ki-67/metabolismo , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Pronóstico , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/patología , Análisis de Regresión , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo
18.
Heart Surg Forum ; 8(6): E431-3, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16283979

RESUMEN

We report a rare case of an inflammatory descending aneurysm. At surgery, the patient had multiple aneurysms on the descending aorta. Histology of the specimen demonstrated an infiltration of chronic inflammatory cells in the aortic media.


Asunto(s)
Aorta Torácica/patología , Aorta Torácica/cirugía , Aneurisma de la Aorta/patología , Aneurisma de la Aorta/cirugía , Aortitis/patología , Aortitis/cirugía , Anciano , Aneurisma Infectado/patología , Aneurisma Infectado/cirugía , Femenino , Humanos , Resultado del Tratamiento
19.
J Invest Dermatol ; 124(3): 651-61, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15737208

RESUMEN

Antibodies directed against the beta chain of the T cell receptor (anti-Vbeta antibodies) are useful to identify the Vbeta repertoire of T cells in various diseases and to quantify numbers of Vbeta-bearing T cells. The goals of this study were to identify Vbeta+ cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the percentage of positive calls with other measures of blood tumor burden, i.e., lymphocyte subsets with a CD4+CD7- and CD4+CD26- phenotype and Sezary cell counts. Thirty-three of 49 (67%) cases of leukemic CTCL reacted with an anti-Vbeta antibody. When combined with reports from the literature, the frequency of Vbeta5 (probably Vbeta5.1) usage was relatively high when compared with Vbeta2 that is also frequently expressed by normal CD4+ T cells. The percentage of Vbeta+ cells correlated to the percentage of CD4+CD7- and CD4+CD26- cells for cases in which the neoplastic cells were deficient in expression of CD7 and CD26, respectively, but not the Sezary cell count. We hypothesize that the increased Vbeta5.1 usage in CTCL may be the result of depletion of Vbeta2 and other Vbeta-bearing T cells by staphylococcal superantigens prior to neoplastic transformation, resulting in a relative increase in the frequency of Vbeta5.1 usage in CTCL.


Asunto(s)
Genes Codificadores de la Cadena beta de los Receptores de Linfocito T/inmunología , Región Variable de Inmunoglobulina/inmunología , Síndrome de Sézary/inmunología , Neoplasias Cutáneas/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndrome de Sézary/fisiopatología , Neoplasias Cutáneas/fisiopatología , Superantígenos/inmunología , Subgrupos de Linfocitos T/inmunología
20.
Cancer Genet Cytogenet ; 154(2): 160-2, 2004 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-15474153

RESUMEN

We describe a novel t(16;18)(p13;q21.3) in a male patient with follicular lymphoma. This unique chromosomal rearrangement has never been described in patients with follicular lymphoma. The breakpoint of 16p13 has several hematopoietic neoplasm-related genes such as MHC2TA, a master regulatory gene for HLA-D, and BCMA, tumor necrosis factor receptor super-family. The majority of follicular lymphomas have a rearrangement of the BCL2 gene, which is a pathogenetic factor in their development. The diagnostic and prognostic significance of this new translocation is yet to be determined.


Asunto(s)
Cromosomas Humanos Par 16 , Cromosomas Humanos Par 18 , Linfoma Folicular/genética , Translocación Genética , Genes bcl-2 , Humanos , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...